AZD1390 FOR RECURRENT GRADE IV GLIOMA
About the Glioblastoma
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/1b clinical trial to evaluate AZD1390 in patients with recurrent WHO grade IV glioma.
The goal of Phase 0 is to confirm that AZD1390 is capable of crossing the blood-brain barrier. Patients with positive results may advance to the 1b expansion phase which combines therapeutic dosing of AZD1390 with standard-of-care fractionated radiotherapy.
The expansion phase will examine progression-free survival and monitor safety and tolerability of AZD1390 in combination with radiation.
- AZD1390 is a highly potent brain penetrant ATM (Ataxia telangiectasia mutant) kinase inhibitor that blocks the repair of DNA breaks caused by radiation treatment.
- AZD1390 is in early clinical development for use as a radiosensitizer in central nervous system malignancies.
- Radiosensitizers make tumor cells more vulnerable to radiation therapy.
Glioblastoma Trial Details
Recurrent WHO Grade IV Glioma
You may be eligible if:
- You are 18 years or older.
- You have had prior resection (surgical removal) of a diagnosed 2021 WHO grade IV glioma and followed standard therapy, including temozolomide and fractionated radiotherapy.
- Your doctor has told you that your tumor has recurred (come back) or has progressed (grown or changed) and you require resection with radiation therapy as part of your post-surgical treatment plan.
Phase 0 Clinical Trial: How it works
Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.
This exposure is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor?
If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the treatment in combination with fractionated radiotherapy in the therapeutic expansion phase.
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.